{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:29:21Z","timestamp":1794227361570,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173668"],"award-info":[{"award-number":["82173668"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373706"],"award-info":[{"award-number":["82373706"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118605","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:01:21Z","timestamp":1769101281000},"page":"118605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery of the first dual PD-L1\/JAK inhibitor with enhanced in vivo antitumor immunity"],"prefix":"10.1016","volume":"306","author":[{"given":"Zhijie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiQi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanle","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-6572","authenticated-orcid":false,"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.118605_bib1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118605_bib2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41577-022-00719-y","article-title":"Tumour immunotherapy: lessons from predator\u2013prey theory","volume":"22","author":"Hamilton","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.118605_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118605_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118605_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118605_bib6","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1021\/acs.jmedchem.3c02143","article-title":"Reducing PD-L1 expression by degraders and downregulators as a novel strategy to target the PD-1\/PD-L1 pathway","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00044-023-03127-6","article-title":"Progress on biphenyl derivatives as PD-1\/PD-L1 inhibitors","volume":"32","author":"Wang","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118605_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bph.16054","article-title":"Optimization of cancer immunotherapy on the basis of programmed death ligand\u20101 distribution and function","volume":"181","author":"Zou","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118605_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/13543776.2024.2368237","article-title":"An updated patent review on PD-1\/PD-L1 antagonists (2022-present)","volume":"34","author":"Uzar","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118605_bib10","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/acs.jmedchem.4c00102","article-title":"Discovery of novel PD-L1 small-molecular inhibitors with potent in vivo anti-tumor immune activity","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib11","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.1021\/acs.jmedchem.3c00731","article-title":"Design, synthesis, and antitumor activity evaluation of 2-arylmethoxy-4-(2,2\u2032-dihalogen-substituted biphenyl-3-ylmethoxy) benzylamine derivatives as potent PD-1\/PD-L1 inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.118605_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116622","article-title":"Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1\/PD-l1 interaction","volume":"275","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib14","doi-asserted-by":"crossref","first-page":"12593","DOI":"10.1021\/acs.jmedchem.5c00344","article-title":"Discovery and crystallography study of novel resorcinol dibenzyl ether-based PD-1\/PD-L1 inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118605_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111717","article-title":"Preclinical development and clinical studies of targeted JAK\/STAT combined Anti-PD-1\/PD-L1 therapy","volume":"130","author":"Chen","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.118605_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2026.118605_bib18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers13040663","article-title":"Recent advancements in the mechanisms underlying resistance to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Yuan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118605_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118605_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107217","article-title":"Small molecule drug discovery targeting the JAK-STAT pathway","volume":"204","author":"Lv","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118605_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118605_bib22","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of Janus kinase (JAK) and histone deacetylase (HDAC) bispecific inhibitors based on the moiety of fedratinib for treatment of both hematologic malignancies and solid cancers","volume":"66","author":"Qiu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib23","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.2174\/1568026622666220307124142","article-title":"Targeting Janus kinase (JAK) for fighting diseases: the research of JAK inhibitor drugs","volume":"29","author":"Zhao","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib24","doi-asserted-by":"crossref","first-page":"eade8520","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118605_bib25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118605_bib26","doi-asserted-by":"crossref","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non\u2013small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118605_bib27","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.tips.2022.04.006","article-title":"Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules","volume":"43","author":"Goebel","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118605_bib29","doi-asserted-by":"crossref","first-page":"15946","DOI":"10.1021\/acs.jmedchem.0c01684","article-title":"Discovery of novel and highly potent resorcinol dibenzyl ether-based PD-1\/PD-L1 inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib30","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1021\/acs.jmedchem.4c02529","article-title":"Discovery of dual PD-L1\/HDAC3 inhibitors for tumor immunotherapy","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118605_bib31","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.4c00553","article-title":"Discovery of small and bifunctional molecules targeting PD-L1\/CD73 for cancer dual immunotherapy","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:57:34Z","timestamp":1773982654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S0223523426000504"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118605","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the first dual PD-L1\/JAK inhibitor with enhanced in vivo antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118605"}}